Search PubMed⌕ Search

Biomedical subjects

A Fogel

Publications and source records attributed to A Fogel.

At least 37 records · Page 2Linked to original sources
PubMed1985

Manual actions of nine- to fifteen-week-old human infants during face-to-face interaction with their mothers.

This paper presents evidence that the manual actions of infants as young as 9 weeks of age may occur in relation to their facial expression, gaze direction, and vocalization. 28 full-term, healthy infants were observed during a 2-min spontaneous face-to-face interaction with their mothers. Videotapes were coded in real time using the following categories of manual action: POINT, SPREAD, CURL, and GRASP. Facial expressions, gaze direction, and vocalizations also were coded for each infant. All of the infants displayed CURL, 20 infants displayed SPREAD, 18 POINTED, and 11 showed GRASP. Right/left differences appeared for the categories CURL, SPREAD, and GRASP, but not for POINT. Hand action was systematically organized into sequences with other infant action. POINT occurred before or after mouthing and vocalization, CURL during vocalization, and SPREAD when the baby was looking away from the mother. The results are discussed in relation to their implications for the ontogeny of nonverbal communicative gestures.

Child Language↗
PubMed1985

Subclinical rubella in pregnancy--occurrence and outcome.

Between the years 1972 and 1979, 40,589 pregnant women were tested for rubella antibodies following suspected illness or exposure, using hemagglutination-inhibition (HI), complement fixation and staphylococcal absorption for determination of specific immunoglobulin M (IgM). Recent primary infection was confirmed by antibody rise in paired sera and/or the presence of specific IgM. Reinfection was differentiated from primary asymptomatic rubella by absence of specific IgM. Determination of neutralizing antibodies was also useful in confirming reinfections. Clinical rubella was confirmed in 1,448 patients (3.6%). In 154 cases asymptomatic rubella infection was detected; 98 had primary infection and 56 experienced reinfection. In a selected group of 2,200 women exposed to confirmed rubella, 6.8% had clinical rubella, 3.8% asymptomatic infection, and in 7.1% the results were doubtful. Reinfection was detected in 12.4% of 265 women with initially low HI titers. The prospective follow-up on pregnancy outcome was available in 87 women with asymptomatic infection. Seven cases of congenital rubella were detected in the group of primary infections, while all 25 children born following reinfection were healthy.

Antibodies, Viral↗
PubMed1983

Viral antibodies in maternal and cord sera.

Viral antibodies were determined in paired maternal and cord blood sera of 258 consecutive deliveries. Antibodies to Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex type 1 (HSV-1), adenovirus (ADV), and varicella zoster (VZV) were tested by indirect immunofluorescence and to rubella (RUB) by hemagglutination inhibition. Analysis of the overall pattern of differences between maternal and cord blood showed a highly significant difference for all six viruses. Analysis regarding individual viruses showed significantly higher titers to CMV and RUB in cord blood, a higher titer to VZV in maternal blood, and similar levels of antibodies to EBV, HSV-1, and ADV in maternal and cord blood. Infants with one or more risk indicators (weight less than 3 kg, Apgar score less than or equal to 7, clinical jaundice, meconium-stained amniotic fluid, respiratory distress syndrome) were defined as "at risk." Infants free of such indicators were defined as "normal." Significantly lower antibody levels to all six viruses were found in both maternal and cord blood of the "at risk" as compared to the "normal" group, while the ratios between the maternal and cord blood levels remained similar. Birth defects were found to have no effect on antibody titers. These results indicate an efficient and selective transfer through the placenta of certain viral antibodies and the possible association of lower antibody production with the presence of risk indicators in the infants.

Antibodies, Viral↗
PubMed1983

Transfer of viral antibodies from mother to infant.

Antibody titers to Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus (HSV) Type 1, varicella-zoster virus (VZV) and rubella virus (RV) were determined in maternal and in newborn cord sera in 258 consecutive deliveries. Infants born with one or more of the following risk factors--weight less than 2.5 kg, Apgar score less than 7, clinical jaundice, meconium-stained amniotic fluid, birth defects and respiratory distress syndrome--were considered to be at risk. Similar geometric mean titers (GMT) of antibodies to EBV and HSV were seen in cord blood. Anti-VZV maternal antibody levels were significantly higher than those of cord blood (P less than 0.01). Levels of antibody to CMV and RV, the two viruses most implicated in fetal damage were significantly higher in cord blood than in maternal blood (P = 0.02, and P less than 0.001, respectively). Lower GMTs of antibodies to all five viruses were found in both maternal and cord sera of the group of infants at risk, as compared with infants without risk factors, while the ratio of maternal to cord blood antibody levels remained similar. It appears that inefficient production of antibodies correlates with the presence of risk factors in the newborn.

Antibodies, Viral↗
PubMed1983

Susceptibility to rubella and borderline immunity.

Immunity to rubella in women of childbearing age has been determined by hemagglutination inhibition (HI) and/or hemolysis in gel (HIG) methods. Susceptibility was defined as absence of antibody at a dilution of 1:16 in HI and a hemolysis zone of less than 7 mm in HIG tests. In screening 30,330 women during the years 1980-81, 13.7% were found seronegative. Among 439 women immunized with RA-27/3 vaccine, 92% showed seroconversion, when tested by HI greater than or equal to 2 months following vaccination. Paired sera from 35 vaccines who remained seronegative were tested by two additional methods: sensitizing antibody (SA) and enzyme-linked immunosorbent assay (ELISA). Ten women were confirmed as vaccine failures by these two methods. The remaining women presented the following results: 19 had borderline and stable titers in their paired sera and 6 showed seroconversion, by SA and ELISA. These results indicate that both SA and ELISA are more sensitive than the HI and HIG tests for evaluation of rubella immunity and response to vaccination.

Antibodies, Viral↗
PubMed1983

Congenital rubella in Israel following the 1978-79 rubella epidemic.

We conducted a retrospective survey of children who were born with congenital rubella syndrome (CR) resulting from a recent rubella epidemic. Sources of information were hospital and laboratory records and data collected in an active search for deaf children born following the epidemic and attending rehabilitation centers for the deaf (Micha). Criteria for inclusion in the survey were: 1) major clinical defects, and 2) one or more of the following positive laboratory findings--virus isolation, presence of rubella-specific IgM antibodies, or the presence of hemagglutination inhibition (HI) antibodies in children beyond the age of 1 year. Excluded from the study were 28 children with persistent HI antibodies, but without clinically detected defects. CR was identified in 45, among them 43 with deafness. Other major defects were psychomotor retardation, microcephaly, cataracts and heart defects. Transient abnormalities included encephalitis, hepatosplenomegaly, jaundice, thrombocytopenia, intrauterine grown retardation and failure to thrive. Thirty-one mothers (70%) reported a history of clinical rubella in pregnancy, the others having experienced subclinical infection. Multiple defects were found in children born following early gestational rubella (less than 2 months); abnormalities also occurred as a consequence of rubella as late as the fifth month of gestation.

Antibodies, Viral↗
PubMed1979

Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line.

A significant aspect of primary hepatic carcinoma in man is the high positive correlation of hepatocellular carcinoma with infection with hepatitis B virus (HBV)1. Analysis of the relationship between HBV infection and oncogenesis is difficult because natural infection with HBV is limited to man and experimental infection has been achieved only in chimpanzees and gibbons. Furthermore, because HBV has not been successfully propagated in cell culture, basic study of virus-cell interaction of the aetiological agent of one of the most widespread infections of man has been impossible. Recently, however, a cell line (PLC/PRF/5) derived from a human hepatoma biopsy was described which produces the HRV surface antigen (HBsAg) and so provides a tool for the experimental investigation of HBV in viro. We now report the derivation and characterisation of two additional cell lines primary liver carcinomas. In contrast to the PLC/PRF/5 cell line, these cell lines retain the capacity to synthesise many human plasma proteins, including both albumin and alpha-fetoprotein (AFP). One of these lines also produces BHsAg. We also present evidence that HBsAg synthesis and secretion in this cell line are correlated with the growth state of the culture. This finding is in contrast to the continuous HBsAg production found in the PLC/PRF/5 cell line.

Albumins↗
PubMed1978

Response to experimental challenge in persons immunized with different rubella vaccines.

The response to experimental challenge with rubella virus was studied in 113 volunteers, ages 13 to 17 years, immunized with three rubella vaccines: HPV-77-DE-5 and Cendehill (inoculated subcutaneously) and RA-27/3 (administered subcutaneously to one group and intranasally to a second group). The occurrence of side effects ranged from 16% in the Cendehill vaccines to 32% in the RA-27/3-intranasal vaccinees. Antibody response to primary vaccination as measured by CF was significantly lower in the Cendehill vaccines. Challenge by intranasal instillation of RA-27/3 a year later produced no adverse effects. Serologic response was measured by testing for CF, HI, and neutralizing and sensitizing antibodies. Booster response, a fourfold increase in antibody fiter after challenge as evidenced by at least one of the tests, occurred in 67% of the Cendehill vaccinees, in 47% of HPV-77 vaccines, and in only 7 to 11% of RA-27/3 vaccinees. Of 37 subjects exhibiting booster response, 27 had an increase in antibody titer demonstrated by two or more serologic tests; 16 of these 27 were Cendehill vaccinees. These results confirm our previous observations and that of others that the RA-27/3 rubella vaccine has the highest immunogenic potential.

Adolescent↗
PubMed1977

Modified staphylococcal absorption method used for detecting rubella-specific immunoglobin M antibodies during a rubella epidemic.

A recently described method for detecting rubella-specific immunoglobulin M (IgM) antibody based on absorption of IgG by Staphylococcus aureus strain Cowan I has been applied to 198 sera collected during a recent rubella epidemic in Israel. Modification of the original method introduced for the present study includes treatment with 2-mercaptoethanol of antibody remaining after absorption by staphylococci. This treatment confirms that the residual antibody is IgM (sensitive to 2-mercaptoethanol) rather than IgG (2-mercaptoethanol resistant). None of the 67 control patients (seropositive for rubella but without history of recent illness or contact) had specific IgM when tested by this method, though 15 showed some residual antibody after staphylococcal absorption. A total of 125 of 131 rubella convalescents (95%) were positive 4 to 49 days after onset of the clinical symptoms. Six patients had no IgM antibodies when tested by the method described, and all were convalescents tested late in relation to onset of clinical symptoms (beyond 3 weeks). When density gradient centrifugation was applied to clarify some results, 2 of 3 convalescents classified as IgM negative by the staphylococcal absorption method did in fact possess IgM antibody. None of 10 controls tested by density gradient centrifugation was IgM positive. This combination of staphylococcal absorption and 2-mercaptoethanol treatment is recommended as a screening test for selection of IgM positives, in addition to the use of a more sensitive method (such as density gradient centrifugation) on at least some samples classified as IgM negative.

Absorption↗
PubMed1976

Serologic studies in 11,460 pregnant women during the 1972 rubella epidemic in Israel.

A total of 11,460 women in the first 4 months of pregnancy, either exposed to or with suspected clinical rubella were tested for rubella antibody during an extensive epidemic of this disease in 1972. The proportion of women who were seronegative decreased from 25% at the beginning of the epidemic to 16% toward the end. In 542 (79%) of 682 cases with suspected clinical rubella, the laboratory findings were consistent with recent rubella infection, while in the remaining 140 cases of suspected clinical rubella recent infection could be excluded by serologic tests. CF tests were more useful than HI for confirmation of clinical rubella, and especially for retrospective diagnosis, since elevated titers (larger than or equal to 1:16) were suggestive of recent infection. Paired sera were tested from 4203 patients exposed to rubella: 1126 of the subjects were seronegative and the remaining 3077 seropositive (HI larger than or equal to 1:16) on first testing. In the seronegative group, 278 seroconversions were detected (24.6%): 247 cases of clinical rubella (21.9%) and 31 seroconversions without clinical symptoms (2.7%). Among the seropositive subjects in 2306 instances (74.9%) recent subclinical rubella could be excluded by low and stable HI or CF antibody titers in paired sera. In 32 (1.1%) an antibody rise (HI or CF) without clinical symptoms was detected, and in the remaining 739 (24%) high CF titers were found in paired sera, and these were classified as suspected subclinical rubella.

Antibodies, Viral↗